Economic outcomes with antidepressant pharmacotherapy: A retrospective intent-to-treat analysis

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 2, 1998, Pages 13-17

  Sclar, David A ^a,b   Skaer, Tracy L ^a,c   Robison, Linda M ^a   Galin, Richard S ^c   Legg, Randall F ^b   Nemec, Neil L ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Qual Med Health Plan of Washington Inc   (United States)

^c Pullman Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; DEPRESSION; DRUG COST; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; DEPRESSIVE DISORDER; DIRECT SERVICE COSTS; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH SERVICES; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 0031980758     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Simon GE, Ormel J, Vonkorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152:352-357
2. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994;9:229-243
3. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-986
4. Johnson J, Weissman M, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-1483
5. Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med 1994;36(9):983-988
6. Jonsson B, Bebbington PE. What price depression? the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673
7. Strum R, Wells KB. How can care for depression become more cost-effective? JAMA 1995;273:51-58
8. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-419
9. Wells KB, Burnam MA. Caring for depression in America: lessons learned from early findings of the Medical Outcomes Study. Psychiatric Medicine 1991;9(4):503-519
10. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA 1995; 273:1026-1031
11. American Psychiatric Association. Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993:150(4, suppl):1-26
12. Agency for Health Care Policy and Research. Clinical Practice Guideline: Depression in Primary Care, vol 2: Treatment of Major Depression. Washington, DC: US Government Printing Office; 1993. AHCPR Publication No. 93-0551
13. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-1361
14. Casey DE. Striking a balance between safety and efficacy: experience with the SSRI sertraline. Int Clin Psychopharmacol 1994;9(3, suppl):5-12
15. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53(2, suppl):61-66
16. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994;55(12, suppl):3-15
17. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97(6, suppl A):24S-32S
18. Rudorfer MV, Manji HK, Porter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994;10:18-46
19. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992;43:3-10
20. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(8, suppl):3-15. Correction 1993;54:491
21. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53
22. White KL, Williams F, Greenberg BG. The ecology of medical care. N Engl J Med 1961;265:885-892
23. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996;275:1897-1902
24. Simon GE, Wagner EH, VonKorff M. Cost-effectiveness comparisons using real world randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-373
25. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57-65
26. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16(4):715-730
27. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995;56(6):556-567
28. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic valuation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995:23(6):395-412
29. Skaer TL, Sclar DA, Robison LM, et al. Antidepressant pharmacotherapy: effect on women's resource utilization within a health maintenance organization. Journal of Applied Therapeutics 1996;1(1):45-52
30. SAS Institute Inc. SAS System Software. Version 6.08. Cary, NC: SAS Institute; 1991
31. Skaer TL. Applying pharmacoeconomic and quality-of-life measures to the formulary management process. Hosp Formul 1993;28(6):577-584